stock · yahoo

Abbott Laboratories

ABT

$90.78
3.79 (4.36%)
polled · warming up

Unten findest du den Live-Kurs für Abbott Laboratories (ABT), einen 1-Jahres-Chart, 8 Indikatoren (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volumen) und einen Vergleichsmodus. Hinzufügen zum Portfolio, auf die Beobachtungsliste setzen oder einen Preisalarm einrichten — alles in einem.

Day
+4.36%
+3.79
Week
+5.19%
+4.48
Month
+4.14%
+3.61
Year
Prev close
$86.99
Volume
$14.12M
Market cap
$158.12B
Currency
USD

Financials

52w high
$139.06
52w low
$81.97
52w change
-35.05%
Day high
$91.48
Day low
$89.20
P/E (TTM)
25.43
Forward P/E
14.98
PEG
1.29
Price / Book
3.04
Beta (5Y)
0.65
Enterprise value
185.6B
EV / Revenue
4.11
EV / EBITDA
15.8
EPS (TTM)
$3.57
Forward EPS
$6.06
Dividend yield
2.78%
Dividend rate
$2.52
Payout ratio
67.23%
Revenue (TTM)
45.13B
EBITDA
11.74B
Free cash flow
6.34B
Total cash
7.3B
Total debt
34.14B
Debt / Equity
64.77
Current ratio
1.39
Quick ratio
0.84
Profit margin
13.90%
Gross margin
56.50%
Return on assets
5.59%
Return on equity
12.33%
Shares outstanding
1.74B
Float
1.73B
Sector: HealthcareIndustry: Medical DevicesHQ: United StatesEmployees: 122Kwww.abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Analyst & Risk

Consensus
Buy
Mean rating1.59 / 5
Analysts24
Next earnings2026-07-16
Strong buy 4Buy 16Hold 7
Analyst price target
$117.29
Mean target · 24 analysts
+29.2%
upside
Low $92.00Now $90.78High $135.00
Beta (vs S&P 500)
0.65
less volatile
52-week change
-35.05%
Short % of float
1.49%
Short ratio (days)
1.63
Debt / Equity
64.77
very high leverage
Current ratio
1.39
Quick ratio
0.84
ROE
12.33%
ROA
5.59%
PEG ratio
1.29
fair
EV / Revenue
4.11
EV / EBITDA
15.8
Revenue growth
7.80%
Earnings growth
-19.70%
EBITDA
11.74B
Free cash flow
6.34B
Total cash
7.3B
Total debt
34.14B
Insider holdings
0.49%
Institutional
82.66%

Recent rating changes

  • 2026-04-27BTIGBuyBuyreit
  • 2026-04-20BarclaysOverweightOverweightmain
  • 2026-04-17Piper SandlerOverweightOverweightmain
  • 2026-04-17OppenheimerOutperformOutperformmain
  • 2026-04-17RBC CapitalOutperformOutperformmain
  • 2026-04-17BenchmarkBuyBuymain
  • 2026-04-17Evercore ISI GroupOutperformOutperformmain
  • 2026-04-17B of A SecuritiesBuyBuymain

Live-Diskussion

Anmelden to join the discussion.

  • Noch keine Kommentare. Sei der Erste.